Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Receptor—Targeted Agents
- 1 November 2005
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 5, S101-S106
- https://doi.org/10.3816/ccc.2005.s.014
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access studyLung Cancer, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- Epidermal growth factor receptor biology (IMC-C225)Current Opinion in Oncology, 2001
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With CisplatinJournal of Clinical Oncology, 2000
- Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical ResultsInvestigational New Drugs, 1999
- Role of an Anti-epidermal Growth Factor Receptor in Treating CancerCancer and Metastasis Reviews, 1999
- The epidermal growth factor receptor and its ligands as therapeutic targets in human tumorsCytokine & Growth Factor Reviews, 1996